Ann: 2022 R&D Tax Refund, page-15

Ask yourselves how the early investors felt who had endured the IPO 2017 ,20c, and the decline to these exact same price levels, prior to the phase 1 trial starting.

Then ask yourselves how they felt when the trial started.
Take a look for yourselves.

How does a market value it at 200m mc ? looking at a new worldwide paradigm in diagnostics.
Nothing has changed, rather it has de-risked from Phase 1 bio kinetics / safety + MRI contrast.
Same train, heading into phase 2 trials. What will the market do, when again it is alerted to the prize that potentially awaits on the success case ? Everything in the market, has to factor what is that prize, risk off, in order to wager a fraction of that, risk on.